Introduction
Prostate cancer is an important health problem throughout the world. Although extensive laboratory and clinical research is ongoing, the issue of when to treat and how to treat prostate cancer remains controversial. This review will focus on major issues in the treatment of prostate cancer for which recent information is available. These issues include neoadjuvant hormonal therapy prior to radical prostatectomy, androgen deprivation combined with external beam radiotherapy, three-dimensional conformal radiation therapy, interstitial low dose rate brachytherapy, and treatment of hormone responsive and hormone resistant advanced prostate cancer.
Neoadjuvant hormonal therapy prior to radical prostatectomy: Does it increase survival?
Radical prostatectomy is reserved for patients with clinically localized prostate cancer. A lower clinical stage when compared to final pathological stage (clinical understaging) remains a challenging problem for urologists because up to two-thirds of patients with clinically organ confined tumors are subsequently identified as having capsular penetration or positive surgical margins [1] [2] [3] [4] [5] . This has led to an interest in neoadjuvant androgen ablation as a possible means of decreasing positive surgical margin rates. A number of randomized studies have shown significant decreases in positive surgical margin rates with three months of neoadjuvant hormonal therapy prior to surgery [6] [7] [8] [9] [10] . For example, Labrie et al. enrolled 161 patients in the first randomized trial of neoadjuvant androgen ablation prior to radical prostatectomy [6] . Patients in the neoadjuvant treatment group received three months of lupron and flutamide prior to surgery. This group was found to have a 7.8% positive surgical margin rate compared to 33.8% in the surgery only group (P = 0.006). Another prospective, multiinstitutional, randomized study found capsular penetration by tumor in 47% of the pre-treatment group versus 78% in the control arm (P < 0.001) [7] . Positive surgical margins were found in 18% of the neoadjuvant therapy group versus 48% of controls (P < 0.001). Goldenberg et al. enrolled 213 patients with clinical stage Tib through T2c disease in a Canadian multicenter, randomized study [10] . The pretreatment group received 12 weeks of the steroidal antiandrogen drug, cyproterone acetate. Positive surgical margin rates were 64.8% in the surgery only group versus 27.7% in the cyproterone acetate group (P = 0.001). A number of histologic changes associated with androgen withdrawal have recently been described by Vailancourt et al. [11] . Nonmalignant prostatic tissue subjected to androgen withdrawal demonstrated prominent hyperplastic basal cell layers, epithelial cell vacuolization and marked decreases in prostatic intraepithelial neoplasia. Cancerous tissue from the neoadjuvant group had smaller nucleoli, cell vacuolization, rare intraluminal crystalloids, higher Gleason grade, lower prevalence of capsular penetration, and less invasion of the perineural spaces when compared to the surgery only group (P < 0.001). Neoadjuvant therapy specimens also had less surgical margin invasion (P -0.002). A recent Swedish trial prospectively evaluated 122 patients who were randomly assigned either to immediate radical prostatectomy or three months of neoadjuvant hormonal treatment with a gonadotropin-releasing hormone agonist followed by radical prostatectomy [12] . The positive margin rate was significantly less in the pretreatment group (23.6% versus 45.5%, P = 0.016). A negative surgical margin was associated with a significantly lower risk of progression than a positive surgical margin (20.8 versus 50.0%, P = 0.0016), and progression was delayed by approximately one year after neoadjuvant therapy. This study at a median follow-up of 38 months did not show any difference in progression-free survival. In summary, although a number of randomized studies have shown decreases in positive surgical margin rates with neoadjuvant hormonal therapy, this has not translated into improved survival or biochemical (PSA) relapse rates. The true utility of this approach will require further follow-up from randomized trials.
Is androgen deprivation combined with external beam radiotherapy better than external beam radiotherapy alone?
Early clinical experiences with a combination of androgen deprivation and external beam radiotherapy in patients with locally advanced disease have been encouraging. In a small trial performed at M.D. Anderson Cancer Center, patients with clinical stage T3-4 adenocarcinoma of the prostate were randomized to receive either radiation alone or radiation with adjuvant diethylstilbesterol (DES) administered until relapse or death. Disease-free survival was significantly improved in the adjuvant DES arm (63% vs. 35% at fifteen years), however, due to intercurrent deaths in patients receiving DES, the overall survival rate was no different between the treatment arms [13] . The toxicity of DES also hindered attempts of the Veterans Administration Cooperative Urological Research Group (VACURG) to definitely assess early use of hormonal therapy in localized prostate cancer [14] .
More modern methods of androgen deprivation with improved safety profiles have allowed cooperative groups in the US and Europe to examine further the efficacy of androgen deprivation in combination with radiation [15] [16] [17] . As outlined in Table 1 , the RTOG and the EORTC have reported preliminary results from three relatively large phase III studies in patients with locally advanced disease. All three studies compared radiation Abbreviations: LF -local failure; DM -distant metastasis; DFSdisease-free survival; OS -overall survival; RTOG -Radiation Therapy Oncology Group; XRT -radiation therapy; G -Goserelin (Zoladex); TAD -total androgen deprivation (Goserelin (Zoladex) + Flutamide (Eulexin)).
therapy to radiation therapy plus some form of androgen deprivation. The results of all studies demonstrate statistically significant higher rates of local control, freedom from distant metastases and disease-free survival with the addition of androgen deprivation. In addition, the EORTC study demonstrated an overall survival advantage was observed at five years for the patients receiving androgen deprivation immediately following radiation therapy. The two RTOG studies to date have not shown a survival advantage, except in selected subgroups of patients (Gleason score 8-10). The results of these studies suggest that androgen deprivation combined with radiation therapy may improve results in patients with locally advanced disease. The optimal timing and duration of androgen deprivation has yet to be established and is the subject of recently completed and ongoing trials within cooperative groups. It is important to note that the outcomes achieved with androgen deprivation and radiotherapy still leave room for improvement.
Is three-dimensional conformal radiation therapy (3DCRT) superior to conventional radiotherapy?
Another approach to improving results with radiation therapy for locally advanced prostate cancer involves increasing the total radiation dose to the prostate and seminal vesicles. With conventional methods of target localization and treatment delivery the maximum dose that can be safely delivered to the prostate is approximately 70 Gray (Gy). Doses above this level have led to substantial problems with rectal and bladder toxicity. The development of sophisticated radiation treatmentplanning computers has allowed for three-dimensional visualization of the prostate and nearby normal structures using the digital information obtained with CTand MR scanners. This advance has allowed radiation oncologists to accurately localize the prostate, seminal vesicles and surrounding normal tissue in three dimensions within individual patients. This localization makes it possible to tailor the radiation portals to the shape of the target tissue and confirm the high-dose volume to the structures thought to contain malignant cells [18] . A number of institutions across the United States and Europe have incorporated three-dimensional treatment techniques into the management of patients with locally advanced prostate cancer. The details of treatment delivery differ slightly among institutions, but the underlying concept, to conform the high-dose radiation volume to the shape of the target tissue in three dimensions, is similar.
Reports from several institutions have documented that 3DCRT is associated with decreased acute and late toxicity [19, 20] . This has allowed for dose escalation of 10%-20% (75-85 Gy) with acceptable toxicity [21, 22] . Combined results from a number of institutions demonstrate that with doses of approximately 75-80 Gy the rate of late grade 2 GI complications is approximately 10%-20%. The incidence of grade 3 or higher GI or GU complications is less than 5% provided the rectal wall is shielded in some fashion to minimize the dose to the anterior rectal wall [21] .
To date the data supporting improved rates of cure with 3DCRT and higher doses are suggestive but not definitive. Hanks et al. have reported that the use of 3DCRT methods leads to improved biochemical relapse free survival when compared to historical controls treated with conventional methods [23] . Hanks has also reported that in patients with pretreatment PSA above 10 ng/ml (Hybritech assay), higher doses are associated with improved biochemical response at three years [23] . On the other hand, a randomized phase III trial performed at the Massachusetts General Hospital showed no overall benefit to the use of higher doses; late toxicity was increased in the high-dose patients [25] . The superiority of 3DCRT or dose escalation can only be ascertained within the context of a prospective, randomized trial. The RTOG is currently accruing patients to a phase I-II dose escalation protocol to determine the maximum tolerated dose that can be given with 3DCRT methods. It is expected that when this trial is completed phase III trials in which patients will be randomly assigned to a standard dose arm or a high-dose conformal arm can be implemented.
Is interstitial low dose rate (LDR) brachytherapy comparable to conventional local treatments?
Perhaps the ultimate in conformal radiation therapy is interstitial brachytherapy. In this technique radioactive sources are placed directly into the prostate gland. A renewed interest has developed for this method because of advances in the technical aspects of radiation delivery and the ability to offer an expedient, cost-effective treatment for clinically localized prostate cancer with potentially less morbidity than can be achieved with external beam radiotherapy or radical prostatectomy [26, 27] .
The results achieved with free-hand placement of radioactive seeds at the time of staging lymphadenectomy were widely viewed as unsatisfactory [28] . These poor results have been attributed to inhomogeneous dose distributions secondary to the unacceptable geometry of the seeds implanted with the free-hand technique. A closer examination of the results achieved in patients with well-differentiated, organ-confined disease shows excellent rates of local control and survival at 15 years that are equivalent to those reported with external beam radiotherapy [28] .
More modern methods rely on transrectal ultrasound (TRUS) or computed tomography (CT) guidance to optimize source distribution within the gland. The radioisotope is generally implanted through the perineum and uniform spacing is ensured by a perineal template. The isotopes used for permanent brachytherapy include 1-125 and Pd-103. Typical peripheral doses are 145 Gy (1-125) and 115 Gy (Pd-103). Depending on the stage of disease interstitial brachytherapy has been used alone or in combination with external beam radiation therapy [26, 27, 29] . The published results with this newer technology usually have a median follow-up of less than five years and are primarily based on serial PSA determinations and posttreatment biopsies. The patients receiving brachytherapy alone are generally selected and the two to five-year biochemical control rates range from 83%-98%. The rates of positive posttreatment biopsy have been reported to be as low as 3% [30] . However, a recent study of 1872 men questioned the results of prior studies particularly in large tumors of high grade [31] ; in this retrospective analysis, patients with clinically localized prostate cancer were treated using interstitial brachytherapy (with or without androgen deprivation) or external beam radiotherapy or radical prostatectomy. Estimates of five-year PSA outcome after these treatments were not statistically different in low-risk patients (stage Tic, T2a and PSA level ^ 10 ng/ml and Gleason score < 6). However, treatment with brachytherapy was inferior, as measured by PSA relapse, in intermediate-risk (stage T2b or Gleason score of 7 or PSA level > 10 and ^ 20 ng/ml) and high-risk (stage T2c or PSA level > 20 ng/ml or Gleason score > 8) patients when compared to conventional radiotherapy or surgery.
Although early results show that interstitial brachytherapy may be efficacious in a subgroup of patients, current follow-up is insufficient to conclude that this treatment is equivalent to conventional radiotherapy or radical prostatectomy; these patients should be involved in clinical trials, so that the long-term outcome of such therapy can be assessed.
Treatment of advanced prostate cancer

Hormone responsive disease Does immediate hormonal therapy for patients with advanced prostate cancer improve survival?
Since the results of the Veterans Administration Cooperative Urological Research Group (VACURG) studies in 1960s and 1970s, it had been generally accepted that most men with advanced prostate cancer did not require treatment until they became symptomatic [14] . The Medical Research Council Prostate Cancer Working Group recently reported the results of a large trial, which challenged the VACURG studies [32] . This study randomized 934 patients with locally advanced or metastatic prostate cancer either to immediate treatment (orchiectomy or luteinizing hormone-releasing hormone analogue) or the same treatment deferred until an indication occurred. Progression from M o to Mi disease and development of metastatic pain occurred more rapidly in deferred patients. Three hundred sixty-one patients died in the deferred arm compared with three hundred twenty-eight in the immediate arm (2P -0.02), with two hundred fifty-seven deaths in the former and two hundred three deaths in the latter from prostate cancer (2/> = 0.001). This was the first study to demonstrate a survival advantage to immediate treatment for advanced prostate cancer. Complications such as spinal cord compression, pathological fractures, and extra-skeletal metastasis occurred more commonly in deferred patients. The overall incidence of serious complications was approximately twice as high in patients who were randomized to deferred treatment.
Although immediate treatment for patients with locally advanced and metastatic prostate cancer appears to improve survival, deferred treatment remains an option for elderly patients with non-metastatic disease as well as those who cannot tolerate long term hormonal therapy. In addition, deferring treatment may be considered for sexually active younger patients for whom maintaining potency is a major determinant of quality of life.
Is maximum androgen blockade (MAB) beneficial in the management of advance prostate cancer?
A number of studies have shown a survival advantage for patients who were treated with MAB [33, 34] . Recently, however, a large randomized trial, which compared MAB with orchiectomy alone in 1387 patients with stage D2 prostate cancer, reported no survival advantage to MAB [35] . This study did show a significant difference in the degree of PSA normalization between the two treatment groups favoring MAB. However, in a companion quality of life (QOL) study to this trial, a consistent pattern of better QOL outcomes for orchiectomized patients with metastatic prostate cancer who received placebo rather than flutamide was found [36] . In addition, two recent but contradictory meta-analyses have been reported: 1) The Prostate Cancer Trialists' Collaborative Group reported the results of a metaanalysis of 22 published trials in which 5710 patients with locally advanced or metastatic prostate cancer were randomized to MAB or castration alone [37] . This meta-analysis showed no survival advantage to MAB; 2) on the other hand, a meta-analysis of 13 published randomized trials, which compared MAB using nonsteroidal antiandrogens to castration alone for the treatment of advanced prostate cancer, showed a statistically significant prolongation of overall survival and progression-free survival in patients who were randomized to be treated with MAB [38] . Thus, the question of whether or not MAB improves survival in advanced prostate cancer patients remains controversial and it may even adversely affect quality of life in this group of patients.
What is the role of intermittent hormonal therapy in advanced prostate cancer?
Androgen deprivation has side effects and it is not a curative treatment for advanced prostate cancer. Over the past several years, investigators have evaluated a variety of methods to diminish side effects from androgen deprivation and improve the quality of life in advanced prostate cancer patients. Several groups have studied intermittent rather than continuous hormone blockade for this purpose [39] [40] [41] [42] [43] . In a pilot British study, 16 patients with metastatic prostate cancer were treated with intermittent androgen deprivation [39] . Eleven patients had a stable hormone response and stopped therapy in three to nine months. Patients remained without treatment for two to eight months and no patient developed irreversible symptoms during this time. Ten out of eleven patients were restarted on hormonal treatment and all of them had a second hormone response. PSA levels in six patients decreased below 2 ng/ml. Another group of investigators studied 41 prostate cancer patients with a mean baseline PSA level of 13 ng/ml and mean Gleason score of 6.3 [40] . Hormonal treatment was given a mean of 18 months and discontinued. It was reinitiated if PSA increased above 5 ng/ml. At the time of publication (in Abstract) 19 out of 41 patients continued to be off hormonal treatment (mean 31 months, range 12-61 months). In a prospective study of 22 patients with stage D2 prostate cancer who were treated with intermittent androgen blockade, all patients reported a reduction of symptoms associated with androgen suppression while off treatment [41] . Thus, at the present time, there is suggestive evidence that intermittent hormone blockade improves quality of life and may delay hormone resistance. Randomized trials are currently in progress with the intent of confirming initial encouraging results and determining impact of this type of treatment on survival.
Is there a role for the combination offinasteride and flutamide in the treatment of advanced prostate cancer?
In a recent phase II study 20 patients with advanced prostate cancer received a combination of finasteride and flutamide [44] . The majority of the patients tolerated the side effects. Sexual potency was preserved in 55% of the patients at a median follow-up of 16.4 months. Authors reported in abstract form an updated follow-up of these patients, including responses to secondary hormonal therapy [45] . At a median follow-up of 35.3 months, 37% of the patients continued to respond. Of the patients who failed this therapy, those who were later treated by castration had secondary hormonal responses, but these appeared to be of shorter duration. The combination offinasteride and flutamide as potency-sparing androgen ablative therapy may be an alternative for some patients with advanced prostate cancer.
What is the role of monotherapy with pure antiandrogens in advanced prostate cancer?
In a randomized trial, Italian Prostate Cancer Group reported 220 patients with advanced prostate cancer who were randomized to receive either bicalutamide monotherapy (150 mg daily) or flutamide plus goserelin until disease progression or toxicity occurred (Abstract) [46] . After a median follow-up time of 20 months, the authors concluded that bicalutamide monotherapy was safe and as effective as MAB. Bicalutamide was better tolerated than MAB and allowed a better quality of life. In another recent study published in abstract form, 1285 patients with advanced prostate cancer were randomized to either bicalutamide monotherapy or castration. Patients who were randomized to bicalutamide monotherapy arm reported subjective well-being comparing to patients who were randomized to castration. Survival was better with castration in Mj patients, although not in Mo patients [47] . Bicalutamide monotherapy may be an option for selected prostate cancer patients.
Is early chemotherapy advantageous in patients with advanced prostate cancer?
Recognizing that androgen deprivation is an effective but non-curative therapy for advanced prostate cancer, some investigators have recently focused on chemotherapy in combination with androgen deprivation as front-line therapy. In a single institution study from Austria, 145 patients with previously untreated advanced prostate cancer were randomly allocated to receive either MAB or MAB and weekly epirubicin for 18 weeks. Although difference in over-all survival was not statistically significant between two groups, patients who were treated with epirubicin and MAB experienced a significantly extended progression-free survival without impairment in the quality of life by epirubicin [48] . In a multi-center study from the Netherlands, 419 patients with locally advanced or metastatic prostate cancer were randomized to either orchiectomy alone or orchiectomy plus estramustine phosphate. Although there was a tendency for slower progression in Mi patients, there was no survival difference between the two groups. Chemotherapy group also experienced larger number of cardiovascular events. It was concluded that hormone/ chemotherapy should be evaluated in younger patients with metastatic disease [49] . Another study reported in abstract form made use of four courses of 78-day, fixedschedule suramin in addition to MAB [50] . Unfortunately, 33 out of 59 patients had toxicity failure (severe neurotoxicity). A recent phase II study reported 50 patients with stage D2 and poor-prognosis stage Dl prostate cancer who were treated with the combination of suramin, leuprolide, and flutamide. The overall response rate was 67%. With a median follow-up duration of 44 months, median survival time has not yet been reached [51] .
Hormone refractory disease
Although initial hormonal therapy is usually effective for palliation, the development of hormone refractory disease limits long-term effectiveness. The management of these patients is an area of active clinical research in prostate cancer:
Is antiandrogen withdrawal beneficial in hormone refractory prostate cancer? A number of studies have shown beneficial effects of flutamide withdrawal after the disease becomes hormone refractory. This antiandrogen withdrawal syndrome has been seen in about 20% of patients. Responses occur following withdrawal of flutamide, bicalutamide, nilutamide and megestrol acetate, but do not usually last more than six months [52, 53] . In a recently published abstract, only 3 out of 30 patients had a greater than 50% decline in PSA which was accompanied by improvement in bone scan. Thus, antiandrogen withdrawal may be beneficial but only in a small number of patients for a limited period.
What is the role ofketoconazole in hormone refractory prostate cancer?
Ketoconazole has been shown to retain activity in hormone refractory prostate cancer which is progressing despite flutamide withdrawal [54] . In one study 55% the patients who were treated with ketoconazole and hydrocortisone in addition to antiandrogen withdrawal have been shown to have a > 50% fall in PSA levels [55] . The duration of PSA response was 8.5 months. At the present time ketoconazole is generally accepted as an active agent in refractory prostate cancer.
Does chemotherapy increase survival in hormone refractory prostate cancer?
Many studies with a variety of chemotherapeutic agents have been reported [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] . A review of selected studies reported during the past two years follows:
1. In a double-blind multi-center Danish study, 131 patients with progressive, metastatic, hormonerefractory prostate cancer were randomized to estramustine phosphate versus placebo [56] . Median time to subjective progression and median overall survival did not differ significantly between two groups. 2. In a phase II trial, 34 patients with advanced prostate cancer who progressed after one or more hormonal therapies and a trial of antiandrogen withdrawal received 96-hour paclitaxel and oral estramustine phosphate [57] . The results demonstrated a 53% PSA response and a median overall survival time of 69 weeks. 3. In a Swiss multi-center phase II study, 30 patients with metastatic hormone-refractory prostate cancer were treated with oral idarubicin [58] . Although toxicity was minimal, no significant response was achieved.
4. Several recent studies demonstrated that oral estramustine and oral etoposide have activity in hormone refractory prostate cancer and they are tolerated well [59] [60] [61] .
Is suramin effective in the treatment of advanced prostate cancer?
In a multi-center, double-blinded, phase III study 458 patients with hormone-refractory prostate cancer who required narcotic analgesics for bone pain were randomized either to suramin and hydrocortisone or placebo and hydrocortisone [67] . Median follow-up was 21 months. Pain response and median duration of pain response were significantly superior in patients who were treated with suramin. Relative risk of progression was 1.0 in the suramin arm comparing to 1.5 in the placebo arm (P -0.0003). Adverse events were comparable in both groups. Neuropathy, which was often reported in previous studies with suramin was seen < 1% of the patients in this trial. Suramin may provide a significant palliative advantage and delay in disease progression in hormone-refractory prostate cancer.
Conclusions
After many years in which few advances in the treatment of prostate cancer could be observed, a number of new observations have been made in the last several years.
-In clinically localized disease, although neoadjuvant hormonal therapy prior to radical prostatectomy decreases positive surgical margin rates, no improvement in survival or biochemical relapse rates have been shown. -In patients with locally advanced disease, androgen deprivation combined with radiation therapy may improve outcome. -There is suggestive evidence that three-dimensional conformal radiation therapy may improve cure rates for locally advanced prostate cancer. -Current data are not sufficient to show that interstitial low dose rate brachytherapy is comparable to more conventional treatments for localized prostate cancer. It may be of use in very selected patients with low-grade tumors and low PSA. -Immediate hormonal therapy for certain patients with advanced prostate cancer improves survival. -Whether or not maximum androgen blockade improves survival remains controversial. It may adversely affect quality of life in patients with metastatic prostate cancer. -Intermittent hormonal therapy may improve quality of life, although effect upon survival is unknown. -Chemotherapy in combination with androgen deprivation is currently being studied as front-line therapy in advanced prostate cancer. -Suramin may provide significant palliative advantage and delay in disease progression in hormone refractory prostate cancer.
